Page last updated: 2024-11-05

violacein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Violacein is a purple pigment produced by various bacteria, including Chromobacterium violaceum. It has a complex structure with a pyrrolo[3,2-b]pyrrole core and an indoline ring system. Violacein exhibits a range of biological activities, including antibacterial, antifungal, antiviral, and anticancer properties. It is synthesized through a complex biosynthetic pathway involving several enzymes. Research into violacein focuses on its potential therapeutic applications, particularly in the development of new antibiotics and anticancer drugs. It is also being investigated for its potential in wound healing and as a natural dye.'

Cross-References

ID SourceID
PubMed CID11053
CHEMBL ID1652263
CHEBI ID131914
SCHEMBL ID151999
SCHEMBL ID15263185
SCHEMBL ID24332448
MeSH IDM0174455

Synonyms (34)

Synonym
4-26-00-00715 (beilstein handbook reference)
qjh0dsq3sg ,
unii-qjh0dsq3sg
548-54-9
CHEBI:131914
(3e)-3-(1,2-dihydro-5-(5-hydroxy-1h-indol-3-yl)-2-oxo-3h-pyrrol-3-ylidene)-1,3-dihydro-2h-indol-2-one
2-indolinone, 3-(2-(5-hydroxyindol-3-yl)-5-oxo-2-pyrrolin-4-ylidene)-
3-(2-(5-hydroxyindol-3-yl)-5-oxo-2-pyrrolin-4-ylidene)-2-indolinone
brn 0049923
oxindole, 3-(2-(5-hydroxyindol-3-yl)-5-oxo-2-pyrrolin-4-ylidene)-
violacein ,
(3e)-3-[5-(5-hydroxy-1h-indol-3-yl)-2-oxo-1,2-dihydro-3h-pyrrol-3-ylidene]-1,3-dihydro-2h-indol-2-one
CHEMBL1652263
SCHEMBL151999
2h-indol-2-one, 3-(1,2-dihydro-5-(5-hydroxy-1h-indol-3-yl)-2-oxo-3h-pyrrol-3-ylidene)-1,3-dihydro-, (3e)-
violacein [mi]
violacein [inci]
SCHEMBL15263185
C21136
3-[1,2-dihydro-5-(5-hydroxy-1h-indol-3-yl)-2-oxo-3h-pyrrol-3-ylidene]-1,3-dihydro-2h-indol-2-one
(e)-3-(5-(5-hydroxy-1h-indol-3-yl)-2-oxo-1,2-dihydro-3h-pyrrol-3-ylidene)indolin-2-one
Q4013798
774154-34-6
(3z)-violacein
3-(5-(5-hydroxy-1h-indol-3-yl)-2-oxo-1,2-dihydro-3h-pyrrol-3-ylidene)indolin-2-one
violacein from janthinobacterium lividum
violacein; 3-(1,2-dihydro-5-(5-hydroxy-1h-indole-3-yl)-2-oxo-3h-pyrrol-3-ylidene)-1,3-dihydro-2h-indole-2-one
Q27225295
SCHEMBL24332448
3-[2-hydroxy-5-(5-hydroxy-1h-indol-3-yl)-1h-pyrrol-3-yl]indol-2-one
DTXSID001028415
AKOS040754806
HY-119809
CS-0078057

Research Excerpts

Overview

Viola is a secondary metabolite produced by several microorganisms including Chromobacterium violaceum. It is formed from tryptophan by five enzymes encoded by a single operon. Violacein is a naturally found pigment that is used by some gram negative bacteria to defend themselves from various Gram negative bacteria.

ExcerptReferenceRelevance
"Violacein is a violet pigment extracted from the gram-negative bacterium Chromobacterium violaceum. "( Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
Blanco, YC; Brocchi, M; Costa, FT; Duran, N; Facchini, G; Goelnitz, U; Justo, GZ; Lopes, SC; Nogueira, PA; Rodrigues, FL; Wunderlich, G, 2009
)
3.24
"Violacein is a secondary metabolite mainly produced by Gram-negative bacteria that is formed from tryptophan by five enzymes encoded by a single operon. "( Functional characterization of a novel violacein biosynthesis operon from Janthinobacterium sp. B9-8.
Chu, X; Du, B; Huang, C; Jiang, L; Xie, C; Xu, X; Zhang, Z, 2022
)
2.43
"Violacein is a secondary metabolite produced by several microorganisms including Chromobacterium violaceum, and it is already used in food and cosmetics. "( Violacein negatively modulates the colorectal cancer survival and epithelial-mesenchymal transition.
Akagi, EM; Carvalho, HF; Clerici, SP; de Souza Oliveira, PF; Durán, N; Faria, AVS; Ferreira-Halder, CV; Justo, GZ, 2022
)
3.61
"Violacein is an important natural antimicrobial pigment that is mainly produced by Chromobacterium violaceum and Janthinobacterium lividum. "( Violacein and its antifungal activity: comments and potentialities.
Castro, GR; Durán, M; Durán, N; Fávaro, WJ; Nakazato, G; Portela, RWD; Tasic, L, 2022
)
3.61
"Violacein is a violet pigment found in several gram-negative bacteria possessing antimicrobial properties to gram-positive bacteria."( Discerning perturbed assembly of lipids in a model membrane in presence of violacein: Effects of membrane hydrophobicity.
Ghosh, SK; Gupta, R, 2023
)
1.86
"Violacein is a pigment synthesized by gram-negative bacteria with various biological activities such as antimicrobial, antiviral, and anticancer activities. "( Structural basis for substrate binding and catalytic mechanism of the key enzyme VioD in the violacein synthesis pathway.
Gao, M; Ran, T; Sun, B; Wang, W; Xu, D; Xu, M; Zhuang, X, 2023
)
2.57
"Violacein is a pigment synthesized by Gram-negative bacteria such as "( Microbial synthesis of violacein pigment and its potential applications.
Choi, KY; Park, H; Park, S; Yang, YH, 2021
)
2.37
"Violacein is a naturally found pigment that is used by some gram negative bacteria to defend themselves from various gram positive bacteria. "( Discerning perturbed assembly of lipids in a model membrane in presence of violacein.
Chowdhury, S; Das, G; Ghosh, SK; Gupta, R; Mitra, S; Mukhopadhyay, MK; Priyadarshini, R, 2021
)
2.29
"Violacein is a naturally occurring purple pigment, widely used in cosmetics and has potent antibacterial and antiviral properties. "( Biosensor-Assisted Adaptive Laboratory Evolution for Violacein Production.
Gwon, DA; Jung, GY; Lee, JW; Seok, JY, 2021
)
2.31
"Violacein is a bisindole antibiotic that is effective against Gram-positive bacteria while the bacterial predator, Bdellovibrio bacteriovorus HD100, predates on Gram-negative strains. "( Combined Application of Bacterial Predation and Violacein to Kill Polymicrobial Pathogenic Communities.
Choi, SY; Im, H; Mitchell, RJ; Son, S, 2017
)
2.15
"Violacein is a deep violet compound that is produced by a number of bacterial species. "( Antiplasmodial and trypanocidal activity of violacein and deoxyviolacein produced from synthetic operons.
Ajioka, J; Andricopulo, AD; Bilsland, E; Costa, FTM; Krogh, R; Oliver, SG; Roberts, A; Spring, DR; Stokes, JE; Tavella, TA, 2018
)
2.18
"Violacein is a violet pigment produced by Chromobacterium violaceum that possesses several functions such as antibacterial, antiviral, antifungal, and antioxidant activities. "( Impact of violacein from Chromobacterium violaceum on the mammalian gut microbiome.
Antunes, LCM; Barbirato, DDS; de Carvalho, DP; Domingues, RMCP; Hardoim, CCP; Leitão, ÁADC; Lobo, LA; Miranda, KR; Pauer, H; Teixeira, FL, 2018
)
2.33
"Violacein is a tryptophan-derived purple pigment produced by environmental bacteria, which displays multiple biological activities, including strong inhibition of Gram-positive pathogens. "( Violacein Targets the Cytoplasmic Membrane of Bacteria.
Brocchi, M; Carretero, GPB; Cauz, ACG; Cuccovia, IM; Gueiros-Filho, FJ; Mortara, L; Park, P; Saraiva, GKV, 2019
)
3.4
"Violacein is an intensely purple pigment synthesized by various genera of bacteria that has been discovered to have a wide range of interesting biological activities which range from anticarcinogenic to antibacterial. "( Isolation and characterization of violacein from an Antarctic Iodobacter: a non-pathogenic psychrotolerant microorganism.
Atalah, J; Blamey, JM; Blamey, L; Encinas, MV; Gutierrez, F; Muñoz-Ibacache, S; Páez, M; Sun, J; Urzua, M, 2020
)
2.28
"Violacein is a quorum-sensing metabolite and is also an active antimicrobial, anticancer agent."( Synergistic antimicrobial profiling of violacein with commercial antibiotics against pathogenic micro-organisms.
Ravi, V; Sivasubramanian, A; Subramaniam, S, 2014
)
1.39
"Deoxyviolacein is a microbial drug with biological activity against tumors, gram-positive bacteria, and fungal plant pathogens. "( Systems metabolic engineering of Escherichia coli for gram scale production of the antitumor drug deoxyviolacein from glycerol.
Becker, J; de Souza Lima, AO; Porto, LM; Rodrigues, AL; Wittmann, C, 2014
)
1.13
"Violacein is a purple pigment from Chromobacterium violaceum that possesses diverse biological and pharmacological properties. "( Violacein induces cell death by triggering mitochondrial membrane hyperpolarization in vitro.
Agnez-Lima, LF; de Medeiros, SR; de Queiroz, JD; Leal, AM; Lima, TK, 2015
)
3.3
"Violacein is a bisindole pigment occurring as a biosynthetic product of Chromobacterium violaceum and Janthinobacterium lividum. "( Raman spectroscopic study of the Chromobacterium violaceum pigment violacein using multiwavelength excitation and DFT calculations.
Edwards, HG; Jehlička, J; Němec, I; Oren, A, 2015
)
2.1
"Violacein is a novel class of drug exhibiting anticancer and antibiotic activities originated from l-tryptophan."( Complete genome sequence of antibiotic and anticancer agent violacein producing Massilia sp. strain NR 4-1.
Kim, HJ; Myeong, NR; Seong, HJ; Sul, WJ, 2016
)
1.4
"Violacein is a versatile pigment, where it exhibits several biological activities, and every year, it shows increasing commercially interesting uses, especially for industrial applications in cosmetics, medicines and fabrics."( Advances in Chromobacterium violaceum and properties of violacein-Its main secondary metabolite: A review.
Brocchi, M; Castro, GR; Cordi, L; Durán, M; Durán, N; Justo, GZ; Nakazato, G; Tasic, L,
)
1.1
"Violacein is a natural purple pigment of Chromobacterium violaceum with potential medical applications as antimicrobial, antiviral, and anticancer drugs. "( Biosynthesis of Violacein, Structure and Function of l-Tryptophan Oxidase VioA from Chromobacterium violaceum.
Blankenfeldt, W; Daniel, NP; Füller, JJ; Jahn, D; Krausze, J; Moser, J; Rennhack, KE; Röpke, R; Schulz, S, 2016
)
2.22
"The violacein is a commercially potential compound with various applications derived from L-tryptophan."( Engineering Corynebacterium glutamicum for violacein hyper production.
Bi, C; Sun, H; Xiong, B; Zhang, C; Zhao, D, 2016
)
1.18
"Violacein is a bacteria-originated indolocarbazole pigment with potential applications due to its various bioactivities such as anti-tumor, antiviral, and antifungal activities. "( Reconstruction of the violacein biosynthetic pathway from Duganella sp. B2 in different heterologous hosts.
Jiang, PX; Lou, K; Wang, HS; Xing, XH; Zhang, C, 2010
)
2.12
"Violacein is a compound obtained from Chromobacterium violaceum, a bacterium found in the Amazonian region. "( Nanocytotoxicity: violacein and violacein-loaded poly (D, L-lactide-co-glycolide) nanoparticles acting on human leukemic cells.
Anazetti, MC; De Azevedo, MM; Duran, N; Frungillo, L; Marcato, PD; Melo, PS, 2009
)
2.13
"Violacein is a natural violet pigment produced by several gram-negative bacteria, including Chromobacterium violaceum, Janthinobacterium lividum, and Pseudoalteromonas tunicata D2, among others. "( Violacein and related tryptophan metabolites produced by Chromobacterium violaceum: biosynthetic mechanism and pathway for construction of violacein core.
Hoshino, T, 2011
)
3.25
"Violacein (Vio) is an important purple pigment with many potential bioactivities. "( Pathway redesign for deoxyviolacein biosynthesis in Citrobacter freundii and characterization of this pigment.
Fang, MY; He, SY; Jiang, PX; Lou, K; Wang, HS; Xiao, S; Xing, XH; Zhang, RP, 2012
)
2.12
"Violacein is a purple-colored, broad-spectrum antibacterial pigment that has a dimeric structure composed of 5-hydroxyindole, oxindole and 2-pyyrolidone subunits formed by the condensation of two modified tryptophan molecules. "( Sequence analysis and functional characterization of the violacein biosynthetic pathway from Chromobacterium violaceum.
August, PR; Call, KM; Draper, MP; Grossman, TH; Holt, D; MacNeil, IA; Minor, C; Osburne, MS; Pemberton, JM, 2000
)
1.99

Effects

Viola has been associated with the induction of apoptosis in colorectal cancer (CRC) cells. Violacein has been used as a unique pigment in distinct specialty areas, such as medical and industrial fields.

ExcerptReferenceRelevance
"Violacein has different bioactive properties conferring distinct selective advantages, such as defense from predation and interspecific competition. "( Comparative Genomics Reveals Insights into Induction of Violacein Biosynthesis and Adaptive Evolution in
Chakraborty, R; Gushgari-Doyle, S; Kazakov, AE; Stuart, RK; Trotter, V; Wu, X; Yu, X, 2021
)
2.31
"Violacein has been associated with the induction of apoptosis in colorectal cancer (CRC) cells."( Violacein negatively modulates the colorectal cancer survival and epithelial-mesenchymal transition.
Akagi, EM; Carvalho, HF; Clerici, SP; de Souza Oliveira, PF; Durán, N; Faria, AVS; Ferreira-Halder, CV; Justo, GZ, 2022
)
2.89
"Violacein has been used as a unique pigment in distinct specialty areas, such as in medical and industrial fields. "( Patents on Violacein: A Compound with Great Diversity of Biological Activities and Industrial Potential.
Brocchi, M; Castro, GR; Durán, M; Durán, N; Fávaro, WJ; Justo, GZ; Nakazato, G, 2021
)
2.45
"Violacein has antibacterial, antiparasitic, and antiviral activities, and also has the potential of inducing apoptosis in certain cancer cells."( Antiplasmodial and trypanocidal activity of violacein and deoxyviolacein produced from synthetic operons.
Ajioka, J; Andricopulo, AD; Bilsland, E; Costa, FTM; Krogh, R; Oliver, SG; Roberts, A; Spring, DR; Stokes, JE; Tavella, TA, 2018
)
1.46

Treatment

Violaacein treatment reduced the amount of EGFR and AXL receptors in the HT29 cell line. Treatment with violacein showed a significant (p<0.05) dose-dependent reduction in pyrexia in rats.

ExcerptReferenceRelevance
"Violacein treatment reduced the amount of EGFR and AXL receptors in the HT29 cell line."( Violacein negatively modulates the colorectal cancer survival and epithelial-mesenchymal transition.
Akagi, EM; Carvalho, HF; Clerici, SP; de Souza Oliveira, PF; Durán, N; Faria, AVS; Ferreira-Halder, CV; Justo, GZ, 2022
)
2.89
"Violacein treatment induced a shift of glycolytic to oxidative metabolism associated with alteration in mitochondrial efficiency, as indicated by higher oxygen consumption rate."( Violacein switches off low molecular weight tyrosine phosphatase and rewires mitochondria in colorectal cancer cells.
Clerici, SP; de Lima, TI; Durán, N; Faria, AVS; Fernandes-Oliveira, PS; Ferreira-Halder, CV; Fonseca, EMB; Justo, GZ; Silveira, LR, 2022
)
2.89
"Pretreatment with violacein also restored cNOS level to normal and led to attenuation of enhanced apoptosis and gastric microvascular permeability."( Gastroprotective activity of violacein isolated from Chromobacterium violaceum on indomethacin-induced gastric lesions in rats: investigation of potential mechanisms of action.
Al-Dhabi, NA; Antonisamy, P; Arasu, MV; Aravinthan, A; Duraipandiyan, V; Ignacimuthu, S; Kannan, P; Kim, JH, 2014
)
1.02
"Treatment with violacein showed a significant (p<0.05) dose-dependent reduction in pyrexia in rats."( Immunomodulatory, analgesic and antipyretic effects of violacein isolated from Chromobacterium violaceum.
Antonisamy, P; Ignacimuthu, S, 2010
)
0.95

Toxicity

Violaacein presented toxic effect on lymphocytes with IC50 values of 3 and 10 micromol L(-1) for protein content and protein phosphatase activity. Violacein is not only toxic towards adults, but also arrests growth and development of C. elegans.

ExcerptReferenceRelevance
" Violacein presented toxic effect on lymphocytes with IC50 values of 3 and 10 micromol L(-1) for protein content and protein phosphatase activity, respectively."( Violacein cytotoxicity on human blood lymphocytes and effect on phosphatases.
Bromberg, N; Durán, N; Ferreira, CV; Haun, M; Justo, GZ, 2005
)
2.68

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves were obtained and the concentration inhibiting cell growth by 50% (IC50) together with the concentration inhibiting the net cell growth by 50% (GI50) were calculated for both cell lines."( Cytotoxic effects of violacein in human uveal melanoma cell lines.
Burnier, MN; Cools-Lartigue, J; Marshall, JC; Saraiva, VS, 2004
)
0.64
" Importantly, a good linear dose-response model in a wide dose range (2."( Metabolic engineering of the violacein biosynthetic pathway toward a low-cost, minimal-equipment lead biosensor.
Guo, Y; Hui, CY; Li, LM; Yi, J; Zhang, NX; Zhu, DL, 2022
)
1.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID556368Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 7 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556375Antimalarial activity against lethal Plasmodium chabaudi chabaudi AJ infected in C57BL/6 mouse assessed as mouse survival rate at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 14 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556373Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.075 mg/kg/day, ip administered 1 hr post-infection and measured on day 8 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556363Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 3.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 6 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556379Antimalarial activity against Plasmodium falciparum mature blood forms (24 to 48 hrs ring stage) infected in erythrocytes after 24 hrs by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556371Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.075 mg/kg/day, ip administered 1 hr post-infection and measured on day 6 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556364Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 3.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 7 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556367Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 6 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556366Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 5 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556376Antimalarial activity against lethal Plasmodium chabaudi chabaudi AJ infected in C57BL/6 mouse assessed as mouse survival rate at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 16 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556378Antimalarial activity against Plasmodium falciparum young blood forms (0 to 24 hrs ring stage) infected in erythrocytes after 24 hrs by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556362Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 3.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 5 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556365Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 3.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 8 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556381Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 7.5 mg/kg/day, ip administered 5 days post-infection and measured on day 7 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556374Antimalarial activity against lethal Plasmodium chabaudi chabaudi AJ infected in C57BL/6 mouse assessed as mouse survival rate at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 9 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556358Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 5 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556370Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.075 mg/kg/day, ip administered 1 hr post-infection and measured on day 5 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556380Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed inhibition of parasitemia at 7.5 mg/kg/day, ip for 10 days followed by compound withdrawal and measured on day 16 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556357Antimalarial activity against chloroquine-resistant Plasmodium falciparum S20 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556356Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in erythrocytes after 48 hrs by [3H]hypoxanthine incorporation assay2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556361Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 8 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556359Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 6 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556377Toxicity in erythrocytes assessed as red blood cell density at 14 uM after 48 hrs2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556372Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.075 mg/kg/day, ip administered 1 hr post-infection and measured on day 7 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556360Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 7.5 mg/kg/day, ip administered 1 hr post-infection and measured on day 7 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
AID556369Antimalarial activity against nonlethal Plasmodium chabaudi chabaudi AS infected in C57BL/6 mouse assessed as inhibition of parasitemia at 0.75 mg/kg/day, ip administered 1 hr post-infection and measured on day 8 post-infection2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (272)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (1.84)18.7374
1990's2 (0.74)18.2507
2000's55 (20.22)29.6817
2010's158 (58.09)24.3611
2020's52 (19.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.66 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index5.56 (4.65)
Search Engine Demand Index63.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.36%)5.53%
Reviews18 (6.52%)6.00%
Case Studies1 (0.36%)4.05%
Observational0 (0.00%)0.25%
Other256 (92.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]